Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

Autor Liedert, Bernd, Pluim, Dick, Schellens, Jan, Thomale, Jürgen
Vydáno 2006

Bevacizumab

Autor Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Vydáno 2010

Trastuzumab

Autor Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

Autor Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Vydáno 2009

Concise Drug Review: Azacitidine and Decitabine

Autor Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2013

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

Autor van Andel, Lotte, Rosing, Hilde, Schellens, Jan HM, Beijnen, Jos H
Vydáno v Mar Drugs (2018)

Long-term platinum retention after treatment with cisplatin and oxaliplatin

Autor Brouwers, Elke EM, Huitema, Alwin DR, Beijnen, Jos H, Schellens, Jan HM
Vydáno 2008

Inhibitors of mTOR

Autor Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Vydáno 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

Autor Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2013

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling

Autor Gast, Marie-Christine W, Engwegen, Judith YMN, Schellens, Jan HM, Beijnen, Jos H
Vydáno 2008

Lapatinib for Advanced or Metastatic Breast Cancer

Autor Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2012

Concise Drug Review: Pazopanib and Axitinib

Autor van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Vydáno 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

Autor van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Vydáno 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

Autor Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Vydáno v Clin Pharmacokinet (2017)

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL

Autor de Jonge, Milly E, Huitema, Alwin DR, Schellens, Jan HM, Rodenhuis, Sjoerd, Beijnen, Jos H
Vydáno 2005

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications

Autor Liberti, Lawrence, Stolk, Pieter, McAuslane, James Neil, Schellens, Jan, Breckenridge, Alasdair M., Leufkens, Hubert
Vydáno v Oncologist (2015)